Kalamazoo, United States
Proteos, founded in 2003, is a well-established contract research organization specializing in recombinant protein expression and purification services, crucial for drug discovery in the biotechnology and pharmaceutical sectors. The company prides itself on delivering top-tier protein reagents, a vital component in the success of drug R&D projects. Operating with a team of highly skilled scientists, Proteos offers fully customized experimental designs that prioritize data-driven results, enhancing project outcomes.
As a wholly owned subsidiary of NIS, Proteos benefits from a streamlined gene-to-structure workflow, ensuring efficient execution and delivery. Most recently, on January 1, 2025, Proteos received an acquisition investment from NanoImaging Services, signaling sustained interest in their niche capabilities from strategic partners. This investment highlights confidence in Proteos's foundational role in drug discovery and its potential for continued growth in the biotech industry.
